The Fed announced in addition to rate hikes for this year there will also be three next year as well...
Becton Dickinson Avoids Health-Care Flu
05/03/2007 12:00 am EST
Charles Carlson, editor of the DRIP Investor, says medical device maker Becton Dickinson is a solid growth company with strong businesses and a consistently rising dividend.
A lot of health-care stocks are under the weather. Generic competition, the lack of blockbuster drugs, problems in the product approval process, and litigation have all led to many health-care stocks being sickly performers. One exception to the group’s malaise has been Becton, Dickinson & Co. (NYSE: BDX).
The company, a provider of medical diagnostics and devices, is trading around its 52-week high near $80. Consistent earnings growth has been a major driver of these shares. The company’s steady performance, rising dividend stream and solid finances should fuel above-average market gains over the long term. The stock represents a worthwhile holding for the growth portion of a DRIP portfolio.
Becton, Dickinson manufactures and sells medical supplies, devices, laboratory instruments, antibodies, reagents, and diagnostic products through its three segments: BD Medical (roughly 55% of annual sales), BD Diagnostics (30%), and BD Biosciences (15%).
Medical supplies include needles, syringes, intravenous catheters, surgical blades; critical-care monitoring devices, and ophthalmic surgical instruments. Diagnostic products include specimen-collection systems, blood-collection products, blood-culturing systems and rapid diagnostic assays. Products in the biosciences area include cell-imaging systems, monoclonal antibodies and kits, reagent systems for life sciences research, and diagnostic assays.
The company’s track record is impressive. Per-share profits have risen annually for well over a decade. Dividends, too, have consistently marched higher. In fact, Becton, Dickinson is a member of the small group of companies that has raised its dividend annually for at least the last 25 years.
Per share profits are expected to come in around $3.75 in fiscal 2007 ending September. That’s up from $3.28 per share in 2006. Becton Dickinson has beaten consensus earnings estimates in each of the last four quarters. The dividend was recently lifted 14% to a quarterly rate of $0.24½ per share. The stock yields 1.2%.
While not a cheap stock, Becton, Dickinson is not too pricey. These shares trade at 21x the fiscal 2007 consensus earnings estimate of $3.75 per share. That seems a fair multiple given the company’s impressive track record and growth potential. Please note that these shares have not split since 1998, so it would not be surprising to see a stock split from current levels.
Becton, Dickinson offers the attractive combination of dependable earnings growth and a steadily rising dividend stream. That one-two punch should lead to healthy returns for DRIP investors.
Becton, Dickinson’s direct-purchase plan permits initial purchases directly with an initial minimum of $250. The firm will waive the minimum if an investor agrees to automatic monthly investment via electronic debit of a bank account of at least $50. There is no enrollment fee. Purchase fees are just three cents per share.
Bloomberg: The Fed lifts rates and steepens the path through 2020 for more hikes. More from Ziad Jas...
Facebook hasn’t been clear that data might go beyond their data centers, and there is no decen...
There are two primary reasons why anchoring your investing decisions to a market’s Fundamental...